Status:
COMPLETED
Dapagliflozin DPPIV Inhibitor add-on Study
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The ef...
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes
- Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these
- Patients will be screened by a blood test and only those who need additional therapy can be enrolled
Exclusion
- Patients with type 1 diabetes
- Patients with very poorly controlled diabetes
- Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
833 Patients enrolled
Trial Details
Trial ID
NCT00984867
Start Date
October 1 2009
End Date
September 1 2011
Last Update
June 13 2014
Active Locations (88)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Huntsville, Alabama, United States
2
Research Site
Ozark, Alabama, United States
3
Research Site
Anaheim, California, United States
4
Research Site
Chula Vista, California, United States